ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer
Ovarian Cancer
About this trial
This is an interventional treatment trial for Ovarian Cancer focused on measuring stage IV ovarian epithelial cancer, recurrent ovarian epithelial cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically documented ovarian epithelial cancer Metastatic and/or locally recurrent disease that is incurable with standard therapy Must have received 1 or 2 prior regimens of chemotherapy At least 1 regimen must have contained cisplatin or carboplatin Bidimensionally measurable disease Indicator lesion size must be as follows: At least 4-50 cm2 by CT scan At least 1 cm2 by chest xray At least 1 cm2 (e.g., nodules) by physical exam No abdominal adenocarcinoma of unknown origin No borderline ovarian tumor No tumor known to be of primary fallopian tube or peritoneal origin PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: At least 12 weeks Hematopoietic: Platelet count at least 100,000/mm3 Absolute granulocyte count at least 1,500/mm3 No known bleeding disorder Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) AST less than 5 times ULN PT/PTT normal (except when elevated due to therapeutic coumadin) Renal: Creatinine no greater than 2 times ULN Cardiovascular: No significant cardiac dysfunction Neurologic No history of significant neurologic disorder No significant psychiatric disorder Other: Not pregnant or nursing Fertile patients must use effective contraception At least 5 years since prior malignancy and no evidence of recurrence No other serious illness or medical condition No active uncontrolled infection No complete bowel obstruction PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy No other concurrent cytotoxic therapy Endocrine therapy: Not specified Radiotherapy: Recovered from prior radiotherapy At least 4 weeks since radiotherapy to at least 20% of bone marrow Surgery: Not specified Other: As least 28 days since prior investigational agent or new anticancer therapy No concurrent therapeutic heparin No other concurrent investigational therapy
Sites / Locations
- Duluth Clinic
- Memorial Sloan-Kettering Cancer Center
- Cross Cancer Institute
- Lethbridge Cancer Clinic
- Burnaby Hospital Regional Cancer Centre
- Penticton Regional Hospital
- British Columbia Cancer Agency - Fraser Valley Cancer Centre
- Prostate Centre at Vancouver General Hospital
- BC Cancer Agency
- St. Paul's Hospital - Vancouver
- British Columbia Cancer Agency - Vancouver Island Cancer Centre
- CancerCare Manitoba
- Moncton Hospital
- Doctor Leon Richard Oncology Centre
- Saint John Regional Hospital
- Dr. H. Bliss Murphy Cancer Centre
- Nova Scotia Cancer Centre
- Queen Elizabeth II Health Science Center
- Royal Victoria Hospital, Barrie
- Peel Memorial Hospital
- Cancer Care Ontario-Hamilton Regional Cancer Centre
- Kingston Regional Cancer Centre
- Cancer Care Ontario-London Regional Cancer Centre
- Trillium Health Centre
- Credit Valley Hospital
- York County Hospital
- North York General Hospital, Ontario
- Lakeridge Health Oshawa
- Ottawa Regional Cancer Center - General Division
- Ottawa Regional Cancer Centre - Civic Campus
- Peterborough Oncology Clinic
- Algoma District Medical Group
- Scarborough Hospital - General Site
- Hotel Dieu Hospital - St. Catharines
- Northeastern Ontario Regional Cancer Centre, Sudbury
- Northwestern Ontario Regional Cancer Centre, Thunder Bay
- Toronto East General Hospital
- Toronto Sunnybrook Regional Cancer Centre
- St. Michael's Hospital - Toronto
- Mount Sinai Hospital - Toronto
- Toronto General Hospital
- Princess Margaret Hospital
- Women's College Campus, Sunnybrook and Women's College Health Science Center
- Saint Joseph's Health Centre - Toronto
- Humber River Regional Hospital
- Cancer Care Ontario - Windsor Regional Cancer Centre
- Queen Elizabeth Hospital, PEI
- Centre Universitaire de Sante de l'Estrie
- Centre Hospitalier Regional de Lanaudiere
- Maisonneuve-Rosemont Hospital
- McGill University Department of Oncology
- Hotel Dieu de Montreal
- Centre Hospitalier de l'Universite de Montreal
- Centre Hospitalier de l'Universite' de Montreal - Pavillon Saint-Luc, Montreal
- Royal Victoria Hospital - Montreal
- Montreal General Hospital
- St. Mary's Hospital Center
- Queen Elizabeth Hospital, Montreal
- Hopital Du Sacre-Coeur de Montreal
- Centre Hospitalier Universitaire de Quebec, Pavillion de Quebec
- Hopital du Saint-Sacrament, Quebec
- Hopital du Haut-Richelieu
- Hopital Laval
- Allan Blair Cancer Centre
- Saskatoon Cancer Centre
- Royal South Hants Hospital
Arms of the Study
Arm 1
Experimental
ISIS 5132
ISIS 5132 x 21 days IV infusion